

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-21 (cancelled)

Claim 22 (currently amended): A composition for inducing specific B cell anergy to a T cell dependent immunogen implicated in an antibody-mediated pathology comprising a plurality of a conjugate, wherein said conjugate is formable by the conjugation of ~~comprises:~~

(a) ~~at least two analog molecules of the immunogen conjugated to a chemically defined valency platform molecule,~~ wherein said analog molecules bind specifically to surface antibody on B cells to which the T cell-dependent immunogen binds specifically, and wherein the analog molecules lack T cell epitopes; and

(b) a chemically defined valency platform molecule, wherein:

the chemically defined valency platform molecule comprises branching groups; ~~and~~
~~wherein~~

the valency platform molecule contains a specific number of attachment sites whereby the valency of said platform molecule is defined; ~~[[and]]~~

wherein the molecular weight of the valency platform molecules is substantially homogeneous; ~~and wherein~~

the valency platform molecule~~[[s have]]~~ has attachment sites at the same location.

Claim 23 (currently amended): The composition of claim 22, wherein the branching groups are derived from a functional group selected from the group consisting of a diamino acid, ~~triamine,~~ and an amino diacid.

Claim 24 (previously presented): The composition of claim 22, wherein the analog molecules are the same.

Claim 25 (currently amended): The composition of claim 22 ~~comprising conjugates,~~ wherein ~~[[a]]~~ said conjugate comprises four analog molecules.

Claim 26 (currently amended): The composition of claim 22, wherein the analog molecules are selected from the group consisting of carbohydrates, lipids, lipopolysaccharides, polypeptides, peptides, proteins, glycoproteins, and lipoproteins.

Claim 27 (currently amended): The composition of claim 22, wherein the valency platform molecule is substantially non-immunogenic.

Claim 28 (withdrawn): The composition of claim 22, wherein the analog molecule is a protein.

Claim 29 (previously presented): The composition of claim 22, comprising a pharmaceutically acceptable carrier.

Claim 30 (previously presented): The composition of claim 29, wherein the composition is suitable for injection.

Claim 31 (previously presented): The composition of claim 22, wherein the conjugate comprises polyethylene glycol.

Claim 32 (previously presented): The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol.

Claim 33 (previously presented): The composition of claim 22, wherein the conjugate comprises polyethylene glycol having the formula $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$, wherein $r=0$ to 300.

Claim 34 (previously presented): The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol having the formula $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$, wherein $r=0$ to 300.

Claim 35 (previously presented): The composition of claim 22, wherein the valency platform molecule comprises triethylene glycol.

Claim 36 (withdrawn): The composition of claim 22, wherein the antibody mediated pathology is stroke.

Claim 37 (previously presented): The composition of claim 22, wherein the immunogen is an external immunogen.

Claim 38 (previously presented): The composition of claim 37, wherein the external immunogen is a biological drug, allergen or a D immunogen associated with Rh hemolytic disease.

Claim 39 (withdrawn): The composition of claim 22, wherein the immunogen is a self-immunogen.

Claim 40 (withdrawn): The composition of claim 39, wherein the immunogen is a cardiolipin.

Claim 41 (withdrawn-currently amended): The ~~conjugate~~ composition of claim 39, wherein the self-immunogen is that associated with thyroiditis, diabetes, stroke, male infertility, myasthenia gravis, or rheumatic fever.

Claim 42 (previously presented): The composition of claim 22, wherein the immunogen and analog molecules are same chemical class.

Claim 43 (previously presented): The composition of claim 42, wherein the immunogen and the analog molecules are polypeptides.

Claim 44 (withdrawn): The composition of claim 22, wherein the immunogen and the analog molecules are of different chemical classes.

Claim 45 (withdrawn-currently amended): The ~~conjugate~~ composition of claim 22, wherein the antibody-mediated pathology is an autoimmune disorder and the associated immunogen is unidentified.

Claim 46 (currently amended): The ~~conjugate~~ composition of claim 22, wherein the analog molecules are selected from the group consisting of peptides, polypeptides, and proteins.

Claim 47 (withdrawn-currently amended): The ~~conjugate~~ composition of claim 22, wherein the analog molecules are selected from the group consisting of glycoproteins, lipoproteins, carbohydrates, lipids and lipopolysaccharides.

Claim 48 (previously presented): A method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition of claim 29.

Claim 49 (previously presented): A method of treating an individual for an antibody-mediated pathology in which undesired antibodies are produced in response to a T cell-dependent immunogen comprising administering a therapeutically effective amount of the composition of claim 29 to the individual.

Claim 50 (previously presented): A method of making the composition of claim 22, the method comprising forming the conjugates by covalently bonding the analog molecules to the valency platform molecule.

Claim 51 (previously presented): A method of making the composition of claim 29, the method comprising combining the conjugates with a pharmaceutically acceptable carrier.

Claim 52 (new): The composition of claim 22, wherein the branching groups are derived from a functional group that is a triamine.